Beta Drugs Ltd
Beta Drugs Ltd Live Price Chart
Performance
| Previous Close | ₹ 1849.7 |
| High | ₹ 1880.6 |
| Volume | 45819 |
| 52W Range | ₹ 990.1 - ₹ 2807.9 |
| Open | ₹ 1880.6 |
| Low | ₹ 1790.6 |
| Market Cap | ₹ 2207.64 Cr |
Beta Drugs Ltd Technicals
| 20 Day | ₹ 0.000 |
| 50 Day | ₹ 0.000 |
| 100 Day | ₹ 0.000 |
| 200 Day | ₹ 0.000 |
| 20 Day | ₹ 0.000 |
| 50 Day | ₹ 0.000 |
| 100 Day | ₹ 0.000 |
| 200 Day | ₹ 0.000 |
Beta Drugs Ltd Fundamentals
| ROCE | 9.274 |
| P/E Ratio | 112.860 |
| P/B Ratio | 6.470 |
| Industry P/E | 6.470 |
| Debt to Equity | 49.856 |
| ROE | 5.737 |
| EPS | 16.390 |
| Dividend Yield | 0.000 |
| Book Value | 285.745 |
| Face Value | 10.000 |
Beta Drugs Ltd Financials
| Particulars | Y202603 | Y202503 | Y202403 | Y202303 | Y202203 |
|---|---|---|---|---|---|
| Total Revenue | 236.5729 | 226.3912 | 199.350115718 | 158.9174 | 125.7047 |
| Total Expenses | 218.3614 | 200.9811 | 169.867105795 | 133.7079 | 105.5431 |
| Profit After Tax | 14.3345 | 15.4321 | 21.936585427 | 18.8161 | 14.2465 |
Beta Drugs Ltd Shareholding Pattern
| Promoter Holdings | 58.909 % |
| FIIs | 1.373 % |
| DIIs | 6.451 % |
| MutualFund | 0.000 % |
| Retail | 21.996 % |
| Others - | 11.271 % |
About Beta Drugs Ltd
Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017 Beta Drugs is a part of Adley Group. The company is primarily engaged in the manufacturing of oncology products. The products ranges from anti-cancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease. It setup the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new 'state of the art' manufacturing facility for oncology formulations in 2014; developed in-house Albumin bound Paclitaxel in 2015; started in-house API Plant - Adley Labs in 2017. In October, 2017, the Company came up with a Public Issue of 22,96,000 Equity Shares by raising equity capital aggregating Rs 19.5 Crores. The Company set up an Oncology Plant in Uzbekistan in 2018. In 2020, the Company launched GEM-RTU, ADLEAP, ADLANTE, BEXINIB; launched 1st Indian Brand of Dasatinib, BEEDAN. In 2025, the Company launched 1st Indian brand of Sunitinib, ADSUNIB. The Company acquired a 66.09% stake in Nivian Lifescience Private Limited through preferential allotment in FY 2025-26. ...
Similar Stocks
| Ambalal Sarabhai Enterprises Ltd Pharmaceuticals | ₹ 35.00 -0.31 (-0.88%) |
| Amrutanjan Health Care Ltd Pharmaceuticals | ₹ 496.20 +3 (+0.61%) |
| Astrazeneca Pharma India Ltd Pharmaceuticals | ₹ 6,302.00 +3 (+0.05%) |
| Bliss GVS Pharma Ltd Pharmaceuticals | ₹ 654.00 -26.9 (-3.95%) |
| Abbott India Ltd Pharmaceuticals | ₹ 25,715.00 -430 (-1.64%) |
| Cipla Ltd Pharmaceuticals | ₹ 1,377.90 +19.9 (+1.47%) |
FAQs on Beta Drugs Ltd
1. Can I buy Beta Drugs Ltd from PL Capital? ›
2. Does Beta Drugs Ltd pay dividends? ›
3. What is the current share price of Beta Drugs Ltd ? ›
4. What is the 52-week high and low of Beta Drugs Ltd ? ›
5. What is the market capitalisation of Beta Drugs Ltd? ›
6. What is the current P/E ratio of Beta Drugs Ltd? ›
7. What is the current P/B ratio of Beta Drugs Ltd? ›
8. What is the shareholding pattern of Beta Drugs Ltd? ›
9. What is the 1-year return of Beta Drugs Ltd? ›
Start SIP in Beta Drugs Ltd
Invest systematically in stocks with the
PL Capital app
Are you a new user? Open your account
